• Arnold C. PaulinoEmail author
  • Christian Carrie


The current survival outcome for children with medulloblastoma is a remarkable testimony for the multidisciplinary approach in the management of pediatric brain tumors. Children older than 3 years of age who have a less than 1.5 cm2 residual tumor after resection with no evidence of dissemination (M0) are classified as having standard-risk disease, while those with a larger tumor bed residual or with tumor dissemination are classified as having high-risk disease. Treatment for these patients includes craniospinal irradiation followed by a boost to the posterior fossa or posterior fossa tumor bed as well as cisplatin-based chemotherapy. For children younger than 3 years, surgery followed by chemotherapy is the most common treatment approach with or without primary site radiotherapy (RT). Currently, four molecular subtypes of medulloblastoma with prognostic implications have been identified. Current protocols are examining de-escalation of treatment for some children with Wnt-pathway tumors with more aggressive therapy for Group 3 and 4 subtypes.


  1. Ashley DM et al (2012) Induction chemotherapy and conformal radiation therapy for very young children with nonmetastatic medulloblastoma: Children’s Oncology Group study P9934. J Clin Oncol 30(26):3181–3186PubMedPubMedCentralCrossRefGoogle Scholar
  2. Bailey CC et al (1995) Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pediatr Oncol 25(3):166–178PubMedCrossRefGoogle Scholar
  3. Belza MG et al (1991) Medulloblastoma: freedom from relapse longer than 8 years—a therapeutic cure? J Neurosurg 75(4):575–582PubMedCrossRefGoogle Scholar
  4. Bouffet E et al (1992) M4 protocol for cerebellar medulloblastoma: supratentorial radiotherapy may not be avoided. Int J Radiat Oncol Biol Phys 24(1):79–85PubMedCrossRefGoogle Scholar
  5. Brown AP et al (2013) Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. Int J Radiat Oncol Biol Phys 86(2):277–284PubMedPubMedCentralCrossRefGoogle Scholar
  6. Buchsbaum J, Paulino AC (2015) Pediatric brain tumors. In: Riaz N, Lee NY, Lu JJ (eds) Target volume delineation for conformal and intensity-modulated radiation therapy. Springer, Cham, pp 495–514Google Scholar
  7. Camara-Costa H et al (2015) Neuropsychological outcome of children treated for standard risk medulloblastoma in the PNET4 European randomized controlled trial of Hyperfractionated versus standard radiation therapy and maintenance chemotherapy. Int J Radiat Oncol Biol Phys 92(5):978–985PubMedCrossRefGoogle Scholar
  8. Carrie C et al (1992) Quality control of radiotherapeutic treatment of medulloblastoma in a multicentric study: the contribution of radiotherapy technique to tumour relapse. The French Medulloblastoma Group. Radiother Oncol 24(2):77–81PubMedCrossRefGoogle Scholar
  9. Carrie C et al (1999) Impact of targeting deviations on outcome in medulloblastoma: study of the French Society of Pediatric Oncology (SFOP). Int J Radiat Oncol Biol Phys 45(2):435–439PubMedCrossRefGoogle Scholar
  10. Carrie C et al (2009) Online quality control, hyperfractionated radiotherapy alone and reduced boost volume for standard risk medulloblastoma: long-term results of MSFOP 98. J Clin Oncol 27(11):1879–1883PubMedCrossRefGoogle Scholar
  11. Castro-Vita H et al (1980) Medulloblastomas. Rev Interam Radiol 5(3):77–82PubMedGoogle Scholar
  12. Chang CH, Housepian EM, Herbert C Jr (1969) An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 93(6):1351–1359PubMedCrossRefGoogle Scholar
  13. Chintagumpala M, Paulino A, Panigrahy A, Hawkins C, Jae A, Parsons DW (2016) Embryonal and pineal region tumors. In: Poplack DG, Pizzo PA (eds) Principles and practice of pediatric oncology. Wolters Kluwer, Philadelphia, pp 671–699Google Scholar
  14. del Charco JO et al (1998) Medulloblastoma: time-dose relationship based on a 30-year review. Int J Radiat Oncol Biol Phys 42(1):147–154PubMedGoogle Scholar
  15. Deschavanne PJ, Fertil B (1996) A review of human cell radiosensitivity in vitro. Int J Radiat Oncol Biol Phys 34(1):251–266Google Scholar
  16. Douglas JG et al (2004) Concurrent chemotherapy and reduced-dose cranial spinal irradiation followed by conformal posterior fossa tumor bed boost for average-risk medulloblastoma: efficacy and patterns of failure. Int J Radiat Oncol Biol Phys 58(4):1161–1164PubMedCrossRefGoogle Scholar
  17. Doxey D et al (1999) Posterior fossa syndrome: identifiable risk factors and irreversible complications. Pediatr Neurosurg 31(3):131–136PubMedCrossRefGoogle Scholar
  18. Duffner PK et al (1993) Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 328(24):1725–1731PubMedCrossRefGoogle Scholar
  19. Eaton BR et al (2016a) Clinical outcomes among children with standard-risk medulloblastoma treated with proton and photon radiation therapy: a comparison of disease control and overall survival. Int J Radiat Oncol Biol Phys 94(1):133–138PubMedCrossRefGoogle Scholar
  20. Eaton BR et al (2016b) Endocrine outcomes with proton and photon radiotherapy for standard risk medulloblastoma. Neuro-Oncology 18(6):881–887PubMedCrossRefGoogle Scholar
  21. Evans AE et al (1990) The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 72(4):572–582PubMedCrossRefGoogle Scholar
  22. Evans G et al (1993) Congenital anomalies and genetic syndromes in 173 cases of medulloblastoma. Med Pediatr Oncol 21(6):433–434PubMedCrossRefGoogle Scholar
  23. Fouladi M et al (1999) Comparison of CSF cytology and spinal magnetic resonance imaging in the detection of leptomeningeal disease in pediatric medulloblastoma or primitive neuroectodermal tumor. J Clin Oncol 17(10):3234–3237PubMedCrossRefGoogle Scholar
  24. Gajjar A et al (1999) Comparison of lumbar and shunt cerebrospinal fluid specimens for cytologic detection of leptomeningeal disease in pediatric patients with brain tumors. J Clin Oncol 17(6):1825–1828PubMedCrossRefGoogle Scholar
  25. Gajjar A et al (2006) Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 7(10):813–820PubMedCrossRefGoogle Scholar
  26. Gandola L et al (2009) Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma. J Clin Oncol 27(4):566–571PubMedCrossRefGoogle Scholar
  27. Garton GR et al (1990) Medulloblastoma—prognostic factors and outcome of treatment: review of the Mayo Clinic experience. Mayo Clin Proc 65(8):1077–1086PubMedCrossRefGoogle Scholar
  28. Gentet JC et al (1995) Preirradiation chemotherapy including “eight drugs in 1 day” regimen and high-dose methotrexate in childhood medulloblastoma: results of the M7 French Cooperative study. J Neurosurg 82(4):608–614PubMedCrossRefGoogle Scholar
  29. Geyer JR et al (2005) Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children’s Cancer Group. J Clin Oncol 23(30):7621–7631PubMedCrossRefGoogle Scholar
  30. Gibson P et al (2010) Subtypes of medulloblastoma have distinct developmental origins. Nature 468(7327):1095–1099PubMedPubMedCentralCrossRefGoogle Scholar
  31. Goldwein JW et al (1996) Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma). Int J Radiat Oncol Biol Phys 34(4):899–904PubMedCrossRefGoogle Scholar
  32. Grill J et al (2005) Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol 6(8):573–580PubMedCrossRefGoogle Scholar
  33. Gupta T et al (2012) Early clinical outcomes demonstrate preserved cognitive function in children with average-risk medulloblastoma when treated with hyperfractionated radiation therapy. Int J Radiat Oncol Biol Phys 83(5):1534–1540PubMedCrossRefGoogle Scholar
  34. Gurney JG et al (1996) Trends in cancer incidence among children in the U.S. Cancer 78(3):532–541PubMedCrossRefGoogle Scholar
  35. Harisiadis L, Chang CH (1977) Medulloblastoma in children: a correlation between staging and results of treatment. Int J Radiat Oncol Biol Phys 2(9–10):833–841PubMedCrossRefGoogle Scholar
  36. Huang E et al (2002) Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 52(3):599–605PubMedCrossRefGoogle Scholar
  37. Jakacki RI et al (2004) A pilot study of preirradiation chemotherapy and 1800 cGy craniospinal irradiation in young children with medulloblastoma. Int J Radiat Oncol Biol Phys 60(2):531–536PubMedCrossRefGoogle Scholar
  38. Jenkin RD (1969) Medulloblastoma in childhood: radiation therapy. Can Med Assoc J 100(2):51–53PubMedPubMedCentralGoogle Scholar
  39. Jereb B et al (1984) Radiation for medulloblastoma adjusted to prevent recurrence to the cribriform plate region. Cancer 54(3):602–604PubMedCrossRefGoogle Scholar
  40. Johnston DL et al (2009) Medulloblastoma in children under the age of three years: a retrospective Canadian review. J Neuro-Oncol 94(1):51–56CrossRefGoogle Scholar
  41. Johnstone PA et al (2013) Pediatric CSI: are protons the only ethical approach? Int J Radiat Oncol Biol Phys 87(2):228–230PubMedCrossRefGoogle Scholar
  42. Kennedy C et al (2014) Quality of survival and growth in children and young adults in the PNET4 European controlled trial of hyperfractionated versus conventional radiation therapy for standard-risk medulloblastoma. Int J Radiat Oncol Biol Phys 88(2):292–300PubMedCrossRefGoogle Scholar
  43. Korah MP et al (2010) Incidence, risks, and sequelae of posterior fossa syndrome in pediatric medulloblastoma. Int J Radiat Oncol Biol Phys 77(1):106–112PubMedCrossRefGoogle Scholar
  44. Kortmann RD (2014) The chemotherapy before or after radiation therapy does not influence survival of children with high-risk medulloblastomas: results of the multicenter and randomized study of the Pediatric Oncology Group (POG 9031). Strahlenther Onkol 190(1):106–108PubMedCrossRefGoogle Scholar
  45. Kortmann RD et al (2000) Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT ‘91. Int J Radiat Oncol Biol Phys 46(2):269–279PubMedCrossRefGoogle Scholar
  46. Krischer JP et al (1991) Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. J Neurosurg 74(6):905–909PubMedCrossRefGoogle Scholar
  47. Lannering B et al (2012) Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol 30(26):3187–3193PubMedCrossRefGoogle Scholar
  48. Lin CT, Riva-Cambrin JK (2015) Management of posterior fossa tumors and hydrocephalus in children: a review. Childs Nerv Syst 31(10):1781–1789PubMedCrossRefGoogle Scholar
  49. Mazloom A, Zangeneh AH, Paulino AC (2010) Prognostic factors after extraneural metastasis of medulloblastoma. Int J Radiat Oncol Biol Phys 78(1):72–78PubMedCrossRefGoogle Scholar
  50. Merchant TE et al (2008) Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. Int J Radiat Oncol Biol Phys 70(3):782–787PubMedCrossRefGoogle Scholar
  51. Michalski JM et al (2016) Results of COG ACNS0331: A phase III trial of involved-field radiotherapy (IFRT) and low dose craniospinal irradiation (LD-CSI) with chemotherapy in average-risk medulloblastoma: a report from the children’s oncology group. Int J Radiat Oncol Biol Phys 96(5):937–938Google Scholar
  52. Miralbell R et al (2002) Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys 54(3):824–829PubMedCrossRefGoogle Scholar
  53. Moxon-Emre I et al (2014) Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma. J Clin Oncol 32(17):1760–1768PubMedCrossRefGoogle Scholar
  54. Northcott PA et al (2011) Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29(11):1408–1414PubMedCrossRefGoogle Scholar
  55. Oyharcabal-Bourden V et al (2005) Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study. J Clin Oncol 23(21):4726–4734PubMedCrossRefGoogle Scholar
  56. Packer RJ et al (1999) Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children’s Cancer Group study. J Clin Oncol 17(7):2127–2136PubMedCrossRefGoogle Scholar
  57. Packer RJ et al (2006) Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24(25):4202–4208PubMedCrossRefGoogle Scholar
  58. Paraf F, Jothy S, Van Meir EG (1997) Brain tumor-polyposis syndrome: two genetic diseases? J Clin Oncol 15(7):2744–2758PubMedCrossRefGoogle Scholar
  59. Paterson E, Farr RF (1953) Cerebellar medulloblastoma: treatment by irradiation of the whole central nervous system. Acta Radiol 39(4):323–336PubMedCrossRefGoogle Scholar
  60. Paulino AC (1997) Radiotherapeutic management of medulloblastoma. Oncology (Williston Park) 11(6):813–823; discussion 823, 827–8, 831.Google Scholar
  61. Paulino AC et al (2003) Protracted radiotherapy treatment duration in medulloblastoma. Am J Clin Oncol 26(1):55–59PubMedCrossRefGoogle Scholar
  62. Paulino AC et al (2010) Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma. Int J Radiat Oncol Biol Phys 78(5):1445–1450PubMedCrossRefGoogle Scholar
  63. Paulino AC et al (2011) Local control after craniospinal irradiation, intensity-modulated radiotherapy boost, and chemotherapy in childhood medulloblastoma. Cancer 117(3):635–641PubMedCrossRefGoogle Scholar
  64. Pollack IF (1997) Posterior fossa syndrome. Int Rev Neurobiol 41:411–432PubMedCrossRefGoogle Scholar
  65. Ramaswamy V et al (2013) Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol 14(12):1200–1207PubMedPubMedCentralCrossRefGoogle Scholar
  66. Ris MD et al (2001) Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children’s Cancer Group study. J Clin Oncol 19(15):3470–3476PubMedCrossRefGoogle Scholar
  67. Ris MD et al (2013) Intellectual and academic outcome following two chemotherapy regimens and radiotherapy for average-risk medulloblastoma: COG A9961. Pediatr Blood Cancer 60(8):1350–1357PubMedCrossRefGoogle Scholar
  68. Rutkowski S et al (2005) Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352(10):978–986PubMedCrossRefGoogle Scholar
  69. Shaw DW et al (1997) Asymptomatic recurrence detection with surveillance scanning in children with medulloblastoma. J Clin Oncol 15(5):1811–1813PubMedCrossRefGoogle Scholar
  70. Tait DM et al (1990) Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 26(4):464–469PubMedCrossRefGoogle Scholar
  71. Tarbell NJ et al (1991) The change in patterns of relapse in medulloblastoma. Cancer 68(7):1600–1604PubMedCrossRefGoogle Scholar
  72. Tarbell NJ et al (2013) High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). J Clin Oncol 31(23):2936–2941PubMedPubMedCentralCrossRefGoogle Scholar
  73. Taylor RE et al (2003) Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 study. J Clin Oncol 21(8):1581–1591PubMedCrossRefGoogle Scholar
  74. Taylor RE et al (2004) Impact of radiotherapy parameters on outcome in the International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 study of preradiotherapy chemotherapy for M0-M1 medulloblastoma. Int J Radiat Oncol Biol Phys 58(4):1184–1193PubMedCrossRefGoogle Scholar
  75. Taylor RE et al (2005) Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer 41(5):727–734PubMedCrossRefGoogle Scholar
  76. Taylor MD et al (2012) Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123(4):465–472PubMedCrossRefGoogle Scholar
  77. Teo WY et al (2013) Implications of tumor location on subtypes of medulloblastoma. Pediatr Blood Cancer 60(9):1408–1410PubMedCrossRefGoogle Scholar
  78. Torres CF et al (1994) Surveillance scanning of children with medulloblastoma. N Engl J Med 330(13):892–895PubMedCrossRefGoogle Scholar
  79. Verma J et al (2015) Comparison of supine and prone craniospinal irradiation in children with medulloblastoma. Pract Radiat Oncol 5(2):93–98PubMedCrossRefGoogle Scholar
  80. von Bueren AO et al (2011) Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. Neuro-Oncology 13(6):669–679CrossRefGoogle Scholar
  81. von Hoff K et al (2009) Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT’91. Eur J Cancer 45(7):1209–1217CrossRefGoogle Scholar
  82. Walter AW et al (1999) Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children’s Research Hospital. J Clin Oncol 17(12):3720–3728PubMedCrossRefGoogle Scholar
  83. Wolden SL (2013) Protons for craniospinal radiation: are clinical data important? Int J Radiat Oncol Biol Phys 87(2):231–232PubMedCrossRefGoogle Scholar
  84. Wolden SL et al (2003) Patterns of failure using a conformal radiation therapy tumor bed boost for medulloblastoma. J Clin Oncol 21(16):3079–3083PubMedCrossRefGoogle Scholar
  85. Zeltzer PM et al (1999) Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol 17(3):832–845PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Department of Radiation OncologyMD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Radiation OncologyCentre Lyon BerardLyonFrance

Personalised recommendations